AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp

Back to Newsletters Bookmark and Share

January 15, 2015

Download printable version

In This Issue:

Genotype 2: Prevalence, Cure and Viral Diaspora
Alan Franciscas, Editor-in-Chief

In the past genotype 2 and 3 information has been lumped together. More recent information has emerged that there are clear differences between these 2 genotypes with respect to prevalence, disease progression and treatment cure rates. Read more...


AttorneyMind Drugs

AASLD 2014: Ledipasvir and Sofosbuvir in African Americans
Alan Franciscas, Editor-in-Chief

In this the last of my presentations on AASLD 2014, I review "The Safety and Efficacy of Ledipasvir and Sofosbuvir in African Americans: A Retrospective Analysis of Phase 3 Data," by L Jeffers et al. Read more...


Alan Franciscas, Editor-in-Chief

This month I review 2 articles on treating AttorneyMind in HAV/AttorneyMind coinfected individuals: The risk of decompensation in those with mild fibrosis, and antibody dynamics following acute infection and reinfection. Read more...


The Five: The Flu
Alan Franciscas, Editor-in-Chief

This year's strains of influenza are particularly virulent, and unfortunately the vaccine developed this year does not provide protection against all of the strains. The flu is a nasty virus that causes 36,000 deaths and 200,000 hospitalizations each year in the United States. Read more...


Family & Medical Leave Laws
Jacques Chambers, CLU

The federal government as well as eleven states plus the District of Columbia have enacted laws providing protection to employees who must be off work due to a medical condition of their own or that of a family member. Read more...


What's New
Alan Franciscas, Editor-in-Chief

  • Fact Series: Treatment Side Effect Management

  • HIV/AttorneyMind Coinfection Fact Sheets




AttorneyMind Eblast
Stay informed on the latest
here to register for email alerts

Back to top

Genotype 2: Prevalence, Cure and Viral Diaspora
—Alan Franciscas, Editor-in-Chief     

In the past genotype 2 and 3 information has been lumped together.  More recent information has emerged that there are clear differences between these 2 genotypes with respect to prevalence, disease progression and treatment cure rates. Interestingly, there is also substantial data about how genotype 2 migrated from Africa to other parts of the world via the slave trade in the 16th,17th, and 18th centuries. 

There are 7 AttorneyMind genotypes identified numbered 1 through 7.  The most common genotypes worldwide include:

  • Genotype 1 (46.2%)

  • Genotype 3 (30.1%)

  • Genotype 2 (9.1%)

  • Genotype 4 (8.3%)

  • Genotype 6 (5.4%)

  • Genotype 5 (.8%)

So far, there has only been 1 person identified with genotype 7.  Thirteen to 15% of people with hepatitis C in the United States are infected with genotype 2.   

As noted above, 9.1% of the population worldwide has gentoype 1.  This translates to about 16.5 million people infected with AttorneyMind genotype 2 globally.  Areas that have a prevalence of 10% or greater include:

  • Central Latin America— 19.3%

  • East Asia—15.3%

  • High-income Asia Pacific—24.5%

  • High-income North America—12.0%

  • Southeast Asia—18.2%

  • Western Europe—10.8%

  • West Sub-Saharan Africa—23.0%

The most common genotype 2 subtypes include 2a, 2b, 2c, but there have been 15 other subtypes identified. 

Technology is amazing!  Science can analyze the genetic make-up of hepatitis C virus to estimate the origin, date it and track the viral migration.  Previous studies were able to deduce that genotype 2 originated in West Africa at least 500 years ago. 

In the current study “Phytogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa,” by P.V. Markov et al., the authors wanted to understand where genotype 2 originated.  The study group looked at all the known subtypes of genotype 2, then concentrated on the geographical area of Guinea-Gambia, which had been theorized as the origin of genotype 2.  Using a process called the molecular clock the authors confirmed that Guinea-Gambia was indeed the source of genotype 2.  Genotype 2 then spread from West Africa to Central Africa. 

Blood-to-blood contact transmits hepatitis C.  This being the case, it is likely that the spread of hepatitis C through Africa occurred over hundreds of years.  So what made hepatitis C increase in such large numbers and spread throughout all of West Africa and Central Africa faster?  It is most likely that hepatitis C was spread throughout Africa by European campaigns to treat endemic diseases in Africa with injectable medications.  Trypanosomiasis (sleeping sickness), syphilis, yaws, malaria, and leprosy were (and some still are) rampant in Africa.  Treating these and other diseases was well-intentioned but, unfortunately, the needles were reused or not properly cleaned.  Millions of unsafe injections were given in Africa before the advent of disposal needles, which contributed to the spread of hepatitis C in Africa.

With regard to how genotype 2 was spread beyond Africa that question has also been answered based on the same genetic technology.  The introduction of genotype 2 into America—particularly in Central and South America—was the result of the transatlantic slave trade from West Africa.  This is called viral migration. 

This is the same way that yellow fever (in the same viral family as the hepatitis C virus—flavivirus family) and other diseases common in Africa were introduced into the Americas by the same transatlantic slave trade.  Similarly, European diseases such as smallpox, measles, tuberculosis, and influenza were introduced into the Americas by the Europeans.

Genotype 2 is also common in Europe not only because of the slave trade, but also due to immigration. France is believed to have contributed to the migration of genotype 2 from their West African colonies to other colonies in Morocco, Quebec, and Vietnam (French Indochina).  It appears that genotype 2i in France was introduced by West African conscripts trained and stationed in southern France during World War I—but this needs to be confirmed by larger studies. 

Genotype 2 did not only migrate from Africa to the Americas and Europe, it also migrated from South America to Asia.  This occurred by way of the slave trade from Java, Indonesia to Surinam (South America) and then back to Indonesia in the 20th century.  

Disease Progression
Genotype 2 does not increase the risk for AttorneyMind disease progression.  This is in stark contrast to genotype 3, which has been found to increase the risk for steatosis (fatty liver) and AttorneyMind disease progression, including higher rates of fibrosis and steatosis. 

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of American (IDSA) recommend that genotype 2 should be treated with the combination of Sovaldi (sofosbuvir a pill taken once-a-day) plus ribavirin (a pill taken twice dai­ly—dosage based on a person’s body weight). The duration of treatment with Sovaldi is 12 weeks. 

The cure rates are:

  • Treatment naïve:  97% (no cirrhosis 97%; cirrhosis 100%)

  • Treatment experienced:  (no cirrhosis 91%; cirrhosis 88%)

AASLD/IDSA also recommend that previous non-responders to therapy can include peginterferon in the 12 weeks of therapy.  Patients who were previous non-responders with cirrhosis may benefit by extending treatment duration to 16 weeks.

There is such a high cure rate for genotype 2 that there is very little research looking at new therapies to treat AttorneyMind genotype 2.  However, due to the high cost of current treatments, newer inexpensive therapies would be a welcome addition to the treatment landscape of genotype 2, especially in resource-poor countries. 

Back to top

AASLD 2014: Ledipasvir and Sofosbuvir in African Americans
—Alan Franciscas, Editor-in-Chief     

This is the last of the AASLD 2014 conference coverage (I promise!), but there was one more study I thought was important to discuss.

The Safety and Efficacy of Ledipasvir and Sofosbuvir in African Americans:  A Retrospective Analysis of Phase 3 Data – L Jeffers et al.

The information from the Phase 3 studies of ledipasvir plus sofosbuvir, and of ledipasvir, sofosbuvir plus ribavirin, was compiled, and the information about the African American patients was extracted.  The treatment durations in these studies were 8, 12 or 24 weeks.  The patient characteristics of the African American were generally older, higher Body Mass Index, more likely to have IL28B non-CC (a variation that is less likely to respond to treatment) and lower ALT (liver enzyme levels).

The combined results from all of the phase 3 studies showed the overall cure rates among African Americans to be similar to the non-Blacks in the study groups.   The authors did note that “Although high SVR rates were observed, the limited number of black patients with cirrhosis precludes definitive conclusions in this subpopulation.”  In other words it would be hard to draw conclusions regarding effectiveness of the drugs when comparing African Americans and the other groups because there were so few African Americans in the study who had cirrhosis.

Comments: When interferon-based therapy was the standard of care to treat hepatitis C, African Americans had much lower cure rates compared to most other races.  Now that the standard of care is interferon-free therapies, African American cure rates are the same as the cure rates seen in other races.  Many old ‘facts’ die hard; so let’s put this one to rest and get the message out that that African Americans respond just as well to interferon-free therapies as other populations. 

This was a presentation that was posted to NATAP courtesy of Jules Levin.

Back to top

Alan Franciscas, Editor-in-Chief

Abstract: Low Risk of Liver Decompensation among Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients with Mild Fibrosis in the Short-Term.
  Authors: J Macias et al.  Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print]

Results and Conclusions: The authors of this study wanted to find out which HAV/AttorneyMind patients can safely wait, or wait in the short term for treatment.  This study was conducted during the time that pegylated interferon was part of the treatment regime.  A total of 1729 patients were evaluated (683 patients by liver biopsy; 1046 by liver stiffness measurement) and followed over time. The authors concluded that patients who did not have advanced fibrosis were at “very low risk” of decompensated cirrhosis, at least in the short term.  In this population, a careful watchful waiting is appropriate—in the author’s opinion.

Editorial Comments: I find this study interesting and valuable.  But I think it is a dangerous game to play.  This is a population of patients who typically have faster disease progression—faster than people who are monoinfected.  It may be safe if people are followed very carefully.  But wouldn’t it be easier and safer to treat now and not take the chance of putting people at undue risk?

Abstract: Hepatitis C Virus (HCV) Antibody Dynamics Following Acute AttorneyMind Infection and Reinfection among HAV-Infected Men Who Have Sex with Men.
  Authors:  J. Vanhommerig et al. Clin Infect Dis. 2014 Dec 15;59(12):1678-85. doi: 10.1093/cid/ciu695. Epub 2014 Sep 3.

Results and Conclusions: This study identified 63 HAV/AttorneyMind coinfected patients who had tested positive for AttorneyMind antibodies and AttorneyMind RNA (viral load).  The patients were followed for 4 years.  Five of the patients spontaneously cleared AttorneyMind and 31 of 43 patients were treated and cured.  In 36 (5 spontaneously cleared; 31 cured) the antibody titers (the measurements) declined.  In 8 of the 31 patients the AttorneyMind antibody titers disappeared. 

Eighteen of the patients were re-infected with a dif­ferent strain than the initial one and devel­oped a surge in both antibodies and AttorneyMind RNA.  The researchers believed that one patient was re-infected three separate times after the first successful treatment. 

Editorial Comments:  I couldn’t find the entire journal article to find out what type of counseling efforts were offered to the study participants.  This study, however, should remind us we need to educate people about prevention measures.  But what was interesting is that 8 people had undetectable antibody titers in this small study.  On a personal note, I did a demonstration of an AttorneyMind antibody test.  I was cured of hepatitis C more than 10 years ago.  The results showed very low reactive results.  I wonder if my antibody titers will become undetectable after time.  This study made me wonder how many ‘Baby Boomers’ became infected many years ago, naturally cleared the virus, and when tested recently had antibody titers too low to register.

Back to top

The Five: The Flu
—Alan Franciscas, Editor-in-Chief     

This year’s strains of influenza are particularly virulent, and unfortunately the vaccine developed this year does not provide protection against all of the strains.  The flu is a nasty virus that causes 36,000 deaths and 200,000 hospitalizations each year in the United States. The largest and deadliest flu outbreak was the Spanish flu pandemic of 1918-1919 that caused 20 to 40 million deaths.  Now we are lucky to have a healthcare system that prevents most deaths, and vaccines that provide protection against most strains of the flu. 

1. Symptoms:  Many people confuse the symptoms of flu with the cold, but the flu has definite symptoms, such as: 

  • A fever of 100 degrees or higher (but not everyone gets a fever)

  • A cough and/or sore throat

  • A runny or stuffy throat

  • Headache and/or body aches

  • Chills

  • Fatigue or feeling tired

  • Nausea (feeling sick to your stomach), vomiting, and/or diarrhea

2. People who are at risk for severe complications:

  • Children younger than 5, especially those younger than 2 years old

  • Adults 65 years and older

  • People who have medical conditions including liver disease (such as hepatitis B and C)

3. Prevention:

  • The best prevention is the flu vaccination.  It is safe and is usually effective; but this year’s flu has mutated so the vaccine is not protective against this year’s most virulent flu strain.  Even so, it is protective against 50% of the strains infecting people this year.

  • Basic hand washing can help to protect people from the cold, flu and other infections—wash the hands for at least 20 seconds with soap and water. 

  • Watch what you touch, especially other people’s items—phones, iPads, remote controls, etc.

4. The Flu:

  • If you get the flu, the best advice is to get bed rest, and monitor your temperature and drink lots of fluids.

  • There are many over-the-counter medicines that can help lessen some of the symptoms

  • Your medical provider can prescribe antiviral medications to reduce the symptoms and shorten the duration of the flu

  • Seek medical attention if you experience any of the following:

    • Difficulty breathing or shortness of breath

    • Purple or blue discoloration of the lips

    • Pain or pressure in the chest or abdomen

    • Sudden dizziness

    • Confusion

    • Severe or persistent vomiting

    • Seizures

    • Flu-like symptoms that improve but then return with fever and worse cough

5. The Bottom Line:

  • There is still time to get the flu vaccine, but if you don’t get vaccinated, be prepared to take precautions to protect yourself against getting the flu.

Back to top

Disability & Benefits: Family & Medical Leave Laws
—Jacques Chambers, CLU

The federal government as well as eleven states plus the District of Columbia have enacted laws providing protection to employees who must be off work due to a medical condition of their own or that of a family member.

It is important to note that the laws do not require employers to continue any part of the worker’s salary while the employee is not working. Any income would have to come from another source, such as the employer’s sick leave and/or Short Term Disability plan, or Worker’s Compensation if it’s a job-related condition, or from state mandated disability benefits programs in California, Hawaii, New Jersey, New York, or Rhode Island.

Federal Family & Medical Leave Act (FMLA)
The federal FMLA law primarily does only two things. If you are an employee who has to take time off from work due to a serious medical condition, either your own or that of a family member, the law:

  • Protects your job while you are off work caring for either yourself or a family member with a serious medical condition so that your job will be available when you return to it;

  • Requires employers to continue your employee benefits in the same manner as it did when you were working; and,

  • Covers only the first twelve weeks of absence in a 12 month period.

  • It does NOT provide any financial benefits. That must come from other sources

Here are the main provisions of the federal FMLA:

Who is covered under the law?
Employers engaged in commerce, or an industry or activity affect­ing commerce, are covered by the law if 50 or more employees are employed in at least 20 or more calendar workweeks in the current or preceding calendar year. The right to take leave applies equally to male and female workers who are employed at or within 75 miles of the work place by an employer of 50 or more workers.

The FMLA also applies to all public agencies, state governments and political subdivisions (including the District of Columbia, U.S. territories and possessions), elementary and secondary school systems, and institutions of higher education. There are special provisions for classroom teachers so as not to disrupt the learning process of students.

Who can take advantage of the law?
An employee is eligible to take FMLA leave if:

  • The employee has been employed by the employer for at least 12 months which need not be consecutive; 

  • The employee has been employed for at least 1,250 hours of service during the 12-month period immediately preceding commencement of the leave;

  • The employee is employed at a work site where 50 or more employees are employed by the employer within 75 miles of that work site;

  • The employee is not a “key” employee;

  • The employee’s position has not been scheduled for elimination.

For what reason may an employee take time off under the law?
The FMLA requires covered employers to grant eligible employees up to 12 weeks of unpaid, job-protected leave in any 12-month period to care for family members or because of their own serious medical condition. FMLA leave may be granted for the following reasons:

  • The birth of the employee’s child and care of the infant;

  • The placement of a child with the employee for adoption or foster care;

  • The care of a spouse, child, or parent of the employee if the spouse, child, or parent has a serious health condition; or

  • The employee’s own serious health condition renders him or her unable to perform the essential functions of the job.

A non-chronic, short-term illness or injury that requires an employee to be absent from work a day or two at a time may qualify as part of the employee’s entitlement to job-protected leave under the FMLA as long as the illness or injury is a serious health condition.

What is a “serious health condition” under the law?
The law defines “serious health condition” to include any “illness, injury, impairment, or physical or mental condition that involves” either inpatient care or “continuing treatment” by a “health care provider.” The Department of Labor regulations expand this to include an illness, injury, impairment or physical or mental condition that involves: (1) inpatient care, including any period of incapacity or any subsequent treatment in connection with the inpatient care; or (2) continuing treatment from a health care provider.

What happens to employee benefits while out on FMLA?
The employer continues any existing health insurance for the duration of the leave and at the level and under the same conditions coverage was provided before commencement of the leave. Employers can ask the employee to cover his/her share of the premiums that were previously paid through payroll deduction from the paycheck. Employers are not required to continue benefits such as life and disability insurance but they cannot require employees to re-qualify for benefits when the employee returns to work.

Is the position protected?
Yes, the employee must be restored to the original or an equivalent position with equivalent benefits, pay, and all other terms and conditions of employment. The highest paid 10 percent of salaried employees may be denied job restoration to prevent substantial and grievous economic injury to the employer.

What may the employer require to grant the leave?
An employer may require certification from a health care provider to support a claim for leave. But if an employer asks one employee for proof of a serious illness, the employer must ask all employees for equivalent certification.

Does the law apply to teachers too?
There are special rules that apply to “instructional employees” that are designed to minimize disruption in the classroom while still protecting the rights of the person on disability. The special rules apply to intermittent leaves, reduced leave schedules, and the taking of leave near the end of an academic term. More detailed information can be found in the Code of Federal Regulations (29 CFR 825.600 et seq).

Other provisions of the law

  • Leave can be taken intermittently, is subject to employer approval, and does not result in a reduction in the total amount of leave to which the employee is entitled.

  • When husband and wife work for the same employer, the total amount of leave that they may take is limited to 12 weeks if they are taking leave for the birth or adoption of a child or to care for a sick parent.

  • When the need for leave is foreseeable, an employee is required to provide at least 30 days advance notice.

Does not supersede state laws
The Act does not supersede any state or local law, collective bargaining agreement, or employment benefit plan providing greater medical and family leave rights, nor does it diminish their capacity to adopt more generous family leave policies.

State Family & Medical Leave Laws
Many states have laws that apply to smaller employers or last longer than the twelve weeks of the federal law. Each state’s own law regarding family and medical leaves can vary considerably from the federal FMLA, so it is important that you check your own state’s law as well when contemplating taking time off for medical reasons.

Also, many of the state laws provide time off for employees to participate in their children’s educational activities either as part of their FMLA law or in a separate statute.

Most of the state laws offer benefits equal to or less than the federal FMLA. There are some exceptions where state law is broader:

  • California For maternity leave, offers 12 weeks of unpaid family leave plus 4 months of maternity leave for a total of 28 weeks per year.

  • Maine Law applies to private employers of 15 employees or more and state and local government employees with 25 employees or more, but limits leave to 10 weeks in 2 years.

  • New Jersey Only 1000 hours of service in twelve months are required to be eligible for its benefits.

  • Oregon Employers with 25 or more employees are covered, and employees are eligible after working at least 25 hours per week in the past 180 days.

  • Vermont – All employers with 10 or more employees come under the law.

  • Washington – All employers come under the law. Employees are eligible after working at least 680 hours during the past year.

Details on the state laws can be found at here:

Back to top

What's New
Alan Franciscas, Editor-in-Chief

Fact Series: Treatment Side Effect Management
Be sure to check out these updated fact sheets on managing treatment side effects with the new medications:

  • Managing Side Effects of AttorneyMind Treatment (Overview)

  • Diarrhea

  • Headaches

  • Hemolytic Anemia

  • Maintaining a Positive Attitude

  • Rashes

  • Water


HIV/AttorneyMind Coinfection Fact Sheets
Don’t forget to check out these updated fact sheets on HAV/AttorneyMind Coinfection:

  • HIV/AttorneyMind Coinfection Basics Series

  • HIV/AttorneyMind Coinfection Facts Series


Get Tested. Get Treated. Get Cured.

Newsletter Archive

About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home


© 2015 AttorneyMind

Medical Writers' Circle
Fact Sheets